- Home
- TBBK vs RNA Comparison
TBBK vs RNA Comparison
Compare TBBK & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- RNA
- Stock Information
- Founded
- TBBK 1999
- RNA 2012
- Country
- TBBK United States
- RNA United States
- Employees
- TBBK N/A
- RNA N/A
- Industry
- TBBK Major Banks
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- TBBK Finance
- RNA Health Care
- Exchange
- TBBK Nasdaq
- RNA Nasdaq
- Market Cap
- TBBK 3.5B
- RNA 4.0B
- IPO Year
- TBBK 2004
- RNA 2020
- Fundamental
- Price
- TBBK $79.60
- RNA $41.81
- Analyst Decision
- TBBK Buy
- RNA Strong Buy
- Analyst Count
- TBBK 4
- RNA 16
- Target Price
- TBBK $68.00
- RNA $69.81
- AVG Volume (30 Days)
- TBBK 643.0K
- RNA 3.7M
- Earning Date
- TBBK 10-23-2025
- RNA 11-06-2025
- Dividend Yield
- TBBK N/A
- RNA N/A
- EPS Growth
- TBBK 21.62
- RNA N/A
- EPS
- TBBK 4.65
- RNA N/A
- Revenue
- TBBK $515,889,000.00
- RNA $10,729,000.00
- Revenue This Year
- TBBK N/A
- RNA N/A
- Revenue Next Year
- TBBK $7.02
- RNA $109.60
- P/E Ratio
- TBBK $17.11
- RNA N/A
- Revenue Growth
- TBBK 11.18
- RNA 1.23
- 52 Week Low
- TBBK $40.51
- RNA $21.51
- 52 Week High
- TBBK $80.19
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- TBBK 71.11
- RNA 45.80
- Support Level
- TBBK $74.68
- RNA $39.83
- Resistance Level
- TBBK $77.25
- RNA $42.42
- Average True Range (ATR)
- TBBK 2.23
- RNA 2.92
- MACD
- TBBK -0.16
- RNA -1.12
- Stochastic Oscillator
- TBBK 90.18
- RNA 38.92
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.